APA-referens

Modak, S., Kushner, B. H., Basu, E., Roberts, S. S., & Cheung, N. V. (2017). Combination of Bevacizumab, Irinotecan and Temozolomide for Refractory or Relapsed Neuroblastoma: Results of a Phase II Study. Pediatr Blood Cancer.

Chicago-stil citat

Modak, Shakeel, Brian H. Kushner, Ellen Basu, Stephen S. Roberts, och Nai-Kong V. Cheung. "Combination of Bevacizumab, Irinotecan and Temozolomide for Refractory or Relapsed Neuroblastoma: Results of a Phase II Study." Pediatr Blood Cancer 2017.

MLA-referens

Modak, Shakeel, et al. "Combination of Bevacizumab, Irinotecan and Temozolomide for Refractory or Relapsed Neuroblastoma: Results of a Phase II Study." Pediatr Blood Cancer 2017.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.